Fore Biotherapeutics, a Philadelphia, PA-based precision oncology company, raised $75M in Series D funding.
The round was led by SR One and Medicxi, with participation from existing investors OrbiMed, HBM Healthcare Investments, Novartis Venture Fund, 3B Future Health Fund, Cormorant Asset Management, Wellington Management and Samsung Securities. In connection with the financing, Giovanni Mariggi, Partner at Medicxi, has joined FORE Biotherapeutics’ Board of Directors.
Fore Biotherapeutics is a precision oncology company dedicated to developing plixorafenib, a Class 1/V600 and 2 BRAF inhibitor with demonstrated clinical safety and early efficacy signals in the previous Phase 1/2a clinical trial.
Leveraging a proprietary functional genomics platform that can screen a wide range of known mutations for cancer-driving genes, the Fore R&D team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without adequate treatment options.
The company intends to use the funds to accelerate the clinical development of plixorafenib, its novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations.
In addition, Matthew E. Ros will step down as CEO and member of the Board of Directors; Shawn M. Leland, PharmD, RPh, advisor to SR One and former Founder, President, and CEO of Elevation Oncology, appointed interim CEO and member of the Board of Directors.
FinSMEs
12/08/2023